Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | PALB2 L35P |
| Gene Variant Detail | |
| Relevant Treatment Approaches | PARP Inhibitor (Pan) |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| PALB2 L35P | Advanced Solid Tumor | sensitive | PARP Inhibitor (Pan) | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing PALB2 L35P were sensitive to treatment with Lynparza (olaparib) in culture, demonstrating decreased cell survival (PMID: 31636395). | 31636395 |
| PALB2 L35P | osteosarcoma | sensitive | PARP Inhibitor (Pan) | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, osteosarcoma cells expressing PALB2 L35P were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400). | 31586400 |
| PALB2 L35P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) decreased survival of cells expressing PALB2 L35P in culture (PMID: 31636395). | 31636395 | |
| PALB2 L35P | Advanced Solid Tumor | sensitive | PARP Inhibitor (Pan) | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment decreased viability of cells expressing PALB2 L35P in culture (PMID: 31757951). | 31757951 |
| PALB2 L35P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment decreased viability of cells expressing PALB2 L35P in culture (PMID: 31757951). | 31757951 | |
| PALB2 L35P | Advanced Solid Tumor | sensitive | PARP Inhibitor (Pan) | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing PALB2 L35P were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400). | 31586400 |